Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies
RL Morgan, B Baack, BD Smith, A Yartel… - Annals of internal …, 2013 - acpjournals.org
Background: Hepatitis C virus (HCV) is a leading cause of hepatocellular carcinoma (HCC).
In the United States, this form of cancer occurs in approximately 15 000 persons annually. A …
In the United States, this form of cancer occurs in approximately 15 000 persons annually. A …
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
TKH Scheel, CM Rice - Nature medicine, 2013 - nature.com
More than two decades of intense research has provided a detailed understanding of
hepatitis C virus (HCV), which chronically infects 2% of the world's population. This effort has …
hepatitis C virus (HCV), which chronically infects 2% of the world's population. This effort has …
Treatment of HCV infection by targeting microRNA
HLA Janssen, HW Reesink, EJ Lawitz… - … England Journal of …, 2013 - Mass Medical Soc
Background The stability and propagation of hepatitis C virus (HCV) is dependent on a
functional interaction between the HCV genome and liver-expressed microRNA-122 (miR …
functional interaction between the HCV genome and liver-expressed microRNA-122 (miR …
Sofosbuvir for previously untreated chronic hepatitis C infection
E Lawitz, A Mangia, D Wyles… - … England Journal of …, 2013 - Mass Medical Soc
Background In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in
previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 …
previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 …
[PDF][PDF] Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale‐up in the age of direct‐acting antivirals
NK Martin, P Vickerman, J Grebely, M Hellard… - …, 2013 - Wiley Online Library
Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs
(PWID) cannot be achieved by harm reduction interventions such as needle exchange and …
(PWID) cannot be achieved by harm reduction interventions such as needle exchange and …
Current and future therapies for hepatitis C virus infection
Current and Future Therapies for Hepatitis C Virus Infection | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …
Skip to main content The New England Journal of Medicine homepage Advanced Search …
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
R Bartenschlager, V Lohmann, F Penin - Nature Reviews Microbiology, 2013 - nature.com
The availability of the first molecular clone of the hepatitis C virus (HCV) genome allowed
the identification and biochemical characterization of two viral enzymes that are targets for …
the identification and biochemical characterization of two viral enzymes that are targets for …
Hepatitis C virus proteins: from structure to function
D Moradpour, F Penin - Hepatitis C virus: from molecular virology to …, 2013 - Springer
Great progress has been made over the past years in elucidating the structure and function
of the hepatitis C virus (HCV) proteins, most of which are now actively being pursued as …
of the hepatitis C virus (HCV) proteins, most of which are now actively being pursued as …
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) …
C Hézode, H Fontaine, C Dorival, D Larrey, F Zoulim… - Journal of …, 2013 - Elsevier
Background & Aims In phase III trials, the safety profile of triple therapy (pegylated
interferon/ribavirin with boceprevir or telaprevir) seems to be similar in HCV treatment …
interferon/ribavirin with boceprevir or telaprevir) seems to be similar in HCV treatment …
Global control of hepatitis C: where challenge meets opportunity
DL Thomas - Nature medicine, 2013 - nature.com
We are entering an important new chapter in the story of hepatitis C virus (HCV) infection.
There are clear challenges and opportunities. On the one hand, new HCV infections are still …
There are clear challenges and opportunities. On the one hand, new HCV infections are still …